Restoration and maintenance of spermatogenesis by HCG therapy in patients with hypothalamo-hypophyseal damage.
Both gonadotropins are necessary to induce spermatogenesis in man and to recover hypophysectomized males. The patients who suffer from tumoral or traumatic hypothalamo-hypophyseal lesion use to have low endogenous gonadotropins (opposite to hypophysectomized patients), which can produce a minor involution of spermatogenesis. Three patients with postpubertal hypogonadotropic hypogonadism and oligozoospermia were studied. Two of them were operated on for chromophobous adenoma of pituitary, and the other patient had traumatic hypothalamo-hypophyseal lesion. The three patients were treated with 5000 IU HCG/week, associated with testosterone enanthate, in two cases and with bromocryptine in the remaining one. All the patients had normalized spermiogram, but when HCG was interrupted, the sperm count regressed to pretreatment levels in spite of the maintenance of treatment with testosterone or bromocryptine. Minimal amounts of FSH together the testosterone supplied by Leydig cell under the HCG stimulus, are able to recover and maintain the spermatogenesis in these patients.
D000328:Adult; D006063:Chorionic Gonadotropin / Q000627:therapeutic use*; D007987:Gonadotropin-Releasing Hormone; D006062:Gonadotropins / Q000097:blood; D006801:Humans; D007006:Hypogonadism / Q000188:drug therapy; D007030:Hypothalamo-Hypophyseal System / Q000293:injuries*; D007248:Infertility, Male / Q000188:drug therapy / Q000209:etiology; D008297:Male; D010911:Pituitary Neoplasms / Q000150:complications; D011388:Prolactin / Q000097:blood; D013091:Spermatogenesis / Q000187:drug effects*; D013739:Testosterone / Q000097:blood / Q000627:therapeutic use; D013972:Thyrotropin / Q000097:blood; D013973:Thyrotropin-Releasing Hormone
D006063:Chorionic Gonadotropin; D006062:Gonadotropins; D007987:Gonadotropin-Releasing Hormone; D013739:Testosterone; D013973:Thyrotropin-Releasing Hormone; D011388:Prolactin; D013972:Thyrotropin